Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Antagon
Drug ID BADD_D00144
Description Ganirelix is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is utilized frequently in assisted reproduction therapy to control the occurrence of ovulation. The drug exerts its effects by inhibiting the action of GnRH in the pituitary gland, leading to fast suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Ganirelix is used in fertility treatment to prevent premature ovulation that could result in the harvesting of eggs that are too immature to be used in procedures such as in vitro fertilization. Ganirelix is marketed by Merck & Co., Inc. as Orgalutran®.
Indications and Usage For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Marketing Status Prescription
ATC Code H01CC01
DrugBank ID DB06785
KEGG ID D08010
MeSH ID C061018
PubChem ID 16130965
TTD Drug ID D00RJJ
NDC Product Code 35207-0010
Synonyms ganirelix | LHRH, N-acetyl-2-naphthylalanyl(1)-(4-chlorophenylalanyl)(2)-3-pyrdinylalanyl(3)-diethylhomoarginyl(6,8)-alaninamide(10)- | N-Ac-(2-naphthyl)Ala-2-(4-Cl-Phe)-3-(3-pyridinyl-Ala)-6,8-Et2-hArg-10-AlaNH2-LHRH | GnRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)- | LHRH,N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)- | ganirelix acetate | N-acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N(sup 6)-(N,N'-diethylamidino)-D-lysyl-L-leucyl-N(sup 6)-(N,N'-diethylamidino)-L-lysyl-L-prolyl-D-alaninamide diacetate (salt) | ganirelix diacetate | RS-26306-298 | RS 26306 | RS-26306 | Antagon | orgalutran
Chemical Information
Molecular Formula C84H121ClN18O17
CAS Registry Number 124904-93-4
SMILES CCNC(=NCCCCC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN=C(NCC)NCC)C(=O)N1CCCC1C(=O)NC(C)C(=O)N )NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)C l)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC.CC(=O)O.CC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abortion spontaneous18.01.04.001--Not Available
Acrochordon23.10.01.005; 16.26.01.005--Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Congenital anomaly03.02.01.001--Not Available
Cryptorchism21.15.01.001; 05.05.02.002; 03.03.01.001--Not Available
Dermatitis23.03.04.002--Not Available
Developmental delay08.01.03.037--Not Available
Discomfort08.01.08.003--Not Available
Dyspnoea22.02.01.004; 02.01.03.002--
Ectopic pregnancy18.02.02.002--Not Available
Eczema23.03.04.006--
Erythema23.03.06.001--Not Available
Exomphalos07.16.03.002; 03.04.07.001--Not Available
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Haemangioma24.03.06.004; 16.02.01.002--Not Available
Headache17.14.01.001--
Hernia08.01.04.001--Not Available
Hydrocele21.12.02.003; 03.03.01.004--Not Available
Hydrocephalus17.07.01.001--
Hydronephrosis20.01.05.001--Not Available
Hypersensitivity10.01.03.003--
Immune system disorder10.02.01.001--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Joint dislocation15.01.07.002; 12.04.02.007--Not Available
Local reaction08.01.03.012--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages